Altered T Cell Responses in Myalgic Enchephalomeylitis/Chronic Fatigue Syndrome (ME/CFS)
Project Number5R01AI159314-05
Contact PI/Project LeaderSELIN, LIISA KAARINA
Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
Project Summary/Abstract
Myalgic enchephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disorder affecting numerous organ
systems and biological processes. Published data seems to suggest that ME/CFS may be preceded by infection,
and the chronic manifestation of illness may represent an altered host response to infection, or an inability to
resolve inflammation. Previous studies focused on perturbation in cytokines and metabolism have also shown
that CD8 T responses are decreased in ME/CFS. In preliminary studies we examined the frequency, functional
and phenotypic status of CD8 T cells to determine whether they were altered in chronic ME/CFS donors as
compared to healthy donors. We observed an increased CD4:CD8 ratio, altered expression of
exhaustion/activation markers like CTLA4 and 2B4 on CD8 T cells, and decreased production of IFN, TNF
and CD107a/b upregulation following PMA stimulation, all suggesting CD8 T cell exhaustion. This was
associated with a, perhaps compensatory increased frequency of activated CD4+CD8+ T cells in the ME/CFS
donors as compared to healthy controls. Notably, a subset of the CD8 and the CD4+CD8+ T cell populations
were spontaneously producing atypical cytokines, subdividing ME/CFS donors into two subsets: type 1 had an
increased frequency of FoxP3+helios+ Treg-like cells producing IL9 (female donors); type 2 had FoxP3+helios-
cells producing IL17 (male donors). When we examined the T-cell receptor (TCR) repertoire of the CD4+CD8+ T
cell population we found evidence of antigen driven clonal expansions to an unknown antigen at this time,
whether it will be a viral or auto-antigen. We hypothesize that the common theme in ME/CFS is an aberrant
response to an immunological trigger like infection, which results in a permanently dysregulated immune system
as a result of CD8 T cell exhaustion. These studies will identify potential biomarkers and mechanisms driving
the immunopathogenesis of ME/CFS leading to future therapies. We will explore this hypothesis in the following
Aims. Aim 1 we will examine altered CD8 and CD4+CD8+ T-cell responses in ME/CFS: 1) we will determine if
the level of CD8 T cell exhaustion varies with ME/CFS type 1 (female) and Type 2 (male) response and with the
severity of ME/CFS symptoms using a larger ME/CFS cohort; 2) we will examine EBV antigen-specific responses
in ME/CFS donors to determine if a common persistent virus response is altered by the immunosuppressive
state of CD8 T cell exhaustion and further contributing to the disease state of ME/CFS; 3) microarray analyses
will be done on sorted activated T cell subsets to assist in understanding the alterations in the functionality of the
exhausted and activated CD8 and CD4+CD8+ T cell subsets in ME/CFS donors. In Aim 2 we will examine TCR
repertoire of CD8 and CD4+CD8+ T-cell subsets for evidence of antigen driven clonal expansion. Defining the
characteristics of the activated clonally expanded CD8 and CD4+CD8+ T cells would be a major step in the field
potentially leading to the identification a specific infectious or auto-antigen response that could be the main driver
of CD8 T cell exhaustion and the immunological basis of ME/CFS.
Public Health Relevance Statement
Narrative
This proposal will examine the ME/CFS from the perspective that an aberrant response to an immunological
trigger like infection results in a dysregulated immune system that is partially immunosuppressed due to CD8 T
cell exhaustion. These studies will identify potential biomarkers and mechanisms driving the
immunopathogenesis of ME/CFS leading to future therapies.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
603847393
UEI
MQE2JHHJW9Q8
Project Start Date
08-March-2021
Project End Date
28-February-2026
Budget Start Date
01-March-2025
Budget End Date
28-February-2026
Project Funding Information for 2025
Total Funding
$474,267
Direct Costs
$310,655
Indirect Costs
$163,612
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$474,267
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI159314-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI159314-05
Patents
No Patents information available for 5R01AI159314-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI159314-05
Clinical Studies
No Clinical Studies information available for 5R01AI159314-05
News and More
Related News Releases
No news release information available for 5R01AI159314-05
History
No Historical information available for 5R01AI159314-05
Similar Projects
No Similar Projects information available for 5R01AI159314-05